Bob Duggan, Summit CEO (via Summit Investments)
Billionaire Bob Duggan's new antibiotic play fails a Phase III trial, and investors aren't happy
Bob Duggan — the billionaire investor famous for turning Pharmacyclics from a penny stock to a $20 billion company — placed a handsome bet on the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.